Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Net Cash Flow: 2014-2024

Historic Net Cash Flow for Editas Medicine (EDIT) over the last 11 years, with Dec 2024 value amounting to $7.9 million.

  • Editas Medicine's Net Cash Flow fell 17.50% to $25.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.6 million, marking a year-over-year increase of 416.09%. This contributed to the annual value of $7.9 million for FY2024, which is 144.15% up from last year.
  • Editas Medicine's Net Cash Flow amounted to $7.9 million in FY2024, which was up 144.15% from -$17.9 million recorded in FY2023.
  • Editas Medicine's Net Cash Flow's 5-year high stood at $63.8 million during FY2021, with a 5-year trough of -$96.2 million in FY2020.
  • In the last 3 years, Editas Medicine's Net Cash Flow had a median value of -$17.9 million in 2023 and averaged -$24.0 million.
  • Per our database at Business Quant, Editas Medicine's Net Cash Flow soared by 166.33% in 2021 and then crashed by 197.12% in 2022.
  • Over the past 5 years, Editas Medicine's Net Cash Flow (Yearly) stood at -$96.2 million in 2020, then surged by 166.33% to $63.8 million in 2021, then slumped by 197.12% to -$62.0 million in 2022, then skyrocketed by 71.18% to -$17.9 million in 2023, then spiked by 144.15% to $7.9 million in 2024.